We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Commission last week exercised its option with Pfizer/BioNTech for an extra 100 million vaccine doses, for a total of 300 million — enough to vaccinate one third of the EU’s population. Read More
Novartis has received a Complete Response Letter (CRL) from the FDA regarding a new drug application (NDA) for its cholesterol-lowering drug Leqvio (inclisiran). Read More
The World Health Organization has announced that its COVAX program has now reached supply agreements for almost 2 billion doses of several promising COVID-19 vaccine candidates for distribution to less well-off countries next year. Read More
The House and Senate are expected to vote today on a combined fiscal 2021 appropriations and COVID-19 relief legislative package after passing another stopgap spending bill Sunday to keep the federal government funded for 24 hours. Read More
The import, sale and marketing of a competitor to AbbVie’s Botox wrinkle treatment must be stopped for nearly two years, the U.S. International Trade Commission (ITC) ruled this week. Read More
In a Thursday hearing of a congressional committee, two members of the Sackler family and Purdue Pharma’s current president and CEO, Craig Landau, dutifully expressed sorrow for the role played by Purdue’s former flagship product, the painkiller OxyContin (oxycodone), in the opioid abuse crisis that has killed thousands of Americans. Read More
With COVID-19 cases surging across Europe, EC President Ursula von der Leyen announced yesterday that EU countries will start vaccinations with the two-dose Pfizer/BioNTech vaccine on Dec. 27. Read More
Before proceeding with trials that use complex innovative designs (CID), sponsors should meet with the FDA to discuss their plans, according to a final guidance released Wednesday that provides details on the kinds of information to bring to an agency meeting. Read More
A final guidance released yesterday indicates the FDA will limit the kinds of questions generic drug sponsors may submit to the agency to get feedback during drug development. Read More
The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 8-4 on Wednesday, with one abstention, that findings from a study sponsored by the National Institutes of Health (NIH) could support new heart failure indications for the generic drug spironolactone. Read More